Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | Chief Operating Officer | March 04, 2024 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date March 04, 2024 · Filed April 02, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,833 |
Reported balance
Holding disclosure · report date 2024-03-04 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 72,833 F1: The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents RSU awards for up to 72,833 shares that vest on the following performance milestones: 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. |
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2024-03-04 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 4,000 F2: The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents a RSU award that vests in three equal annual installments commencing on the first anniversary of the grant date, December 14, 2021 Upon a change in control of the Issuer, all of the RSUs will vest in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.25 · Expires 2030-10-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-04 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F3: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 10% on the grant date, October 5, 2020, and the remaining 90% of the stock option will vest in equal semi-annual installments over four annual periods. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2031-12-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-04 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance Not disclosed F4: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 25% on the one year anniversary of the grant date, December 14, 2021, and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2033-09-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-04 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance Not disclosed F5: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2033-11-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-04 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance Not disclosed F6: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents RSU awards for up to 72,833 shares that vest on the following performance milestones: 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Upon a change in control of the Issuer, 100% of the RSUs will become fully vested.
F2: The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents a RSU award that vests in three equal annual installments commencing on the first anniversary of the grant date, December 14, 2021 Upon a change in control of the Issuer, all of the RSUs will vest in full.
F3: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 10% on the grant date, October 5, 2020, and the remaining 90% of the stock option will vest in equal semi-annual installments over four annual periods. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
F4: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 25% on the one year anniversary of the grant date, December 14, 2021, and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
F5: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
F6: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $14.56 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 14 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2034-03-01 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F8 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 13 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-03-01 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F8 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,080 | Not disclosed Strike: $14.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 12 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,080 shares Expires 2031-12-14 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 7,080 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 11 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,080 Underlying: Common Stock · 7,080 shares Expires 2031-12-14 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,000 | Not disclosed Strike: $11.25 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 10 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2030-10-05 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 8,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 9 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-10-05 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 8 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2034-10-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 7 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-10-29 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,021 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 6 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,021 shares Expires 2033-09-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 22,021 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 5 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,021 Underlying: Common Stock · 22,021 shares Expires 2033-09-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,194 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 4 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,194 shares Expires 2033-11-06 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 9,194 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 3 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,194 Underlying: Common Stock · 9,194 shares Expires 2033-11-06 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $2.89 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 2 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2035-02-25 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:07 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023340 · wk-form4_1775167665.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-25 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006620 · wk-form4_1770688461.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:38 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000006 · wk-form4_1740609481.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 08:23 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 19,489 | $4.99 | $97,250.11 |
DisclosureSEC source: 0001516551-24-000119 · wk-form4_1732109026.xml · nonDerivative · entry 2 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,259 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| November 15, 2024 Filed Nov 20, 2024 08:23 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 85 | $5.55 | $471.75 |
DisclosureSEC source: 0001516551-24-000119 · wk-form4_1732109026.xml · nonDerivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,748 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:33 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001516551-24-000103 · wk-form4_1730334786.xml · derivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 06:19 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000020 · wk-form4_1709551139.xml · derivative · entry 2 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-03-01 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 06:19 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-24-000020 · wk-form4_1709551139.xml · nonDerivative · entry 1 Diep Tuan Tu · CIK 0002013809 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,833 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.